Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Expert Opinion on Pharmacotherapy
|
February 23, 2022
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature
Alexander Grunenberg, Elisa Sala, Silke Kapp-Schwoerer, et al.
Pathogens (Basel, Switzerland)
|
March 26, 2022
18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
Nina Eberhardt, Lynn Peters, Silke Kapp-Schwoerer, et al.
Leukemia
|
July 28, 2019
TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis
Milena Pantic, Dietmar Pfeifer, Silke Kapp-Schwoerer, et al.
Haematologica
|
May 28, 2021
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
Katrin Teich, Julia Krzykalla, Silke Kapp-Schwoerer, et al.
Hemasphere
|
August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive induction
Konstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
Journal of Hematology & Oncology
|
August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Jonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Hemasphere
|
January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AML
Sibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
Nature Communications
|
May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Sibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Nature Communications
|
March 24, 2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
Sonja Loges, Michael Heuser, Jörg Chromik, et al.
Blood
|
September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Expert Opinion on Pharmacotherapy
|
February 23, 2022
Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature
Alexander Grunenberg, Elisa Sala, Silke Kapp-Schwoerer, et al.
Pathogens (Basel, Switzerland)
|
March 26, 2022
18F-FDG-PET/MR in Alveolar Echinococcosis: Multiparametric Imaging in a Real-World Setting
Nina Eberhardt, Lynn Peters, Silke Kapp-Schwoerer, et al.
Leukemia
|
July 28, 2019
TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis
Milena Pantic, Dietmar Pfeifer, Silke Kapp-Schwoerer, et al.
Haematologica
|
May 28, 2021
Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with <i>nucleophosmin1</i>-mutated acute myeloid leukemia receiving gemtuzumab ozogamicin
Katrin Teich, Julia Krzykalla, Silke Kapp-Schwoerer, et al.
Hemasphere
|
August 27, 2025
A pooled analysis of 3 large multicenter trials confirms a survival advantage for <i>NPM1</i> <sup>mut</sup> AML in MRD<sup>neg</sup> remission after intensive induction
Konstanze Döhner, Hartmut Döhner, Daniela Späth, et al.
Journal of Hematology & Oncology
|
August 16, 2023
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease
Jonas S Heitmann, Richard F Schlenk, Daniela Dörfel, et al.
Hemasphere
|
January 16, 2025
Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with <i>NPM1</i>-mutated AML
Sibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
Nature Communications
|
May 4, 2019
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Sibylle Cocciardi, Anna Dolnik, Silke Kapp-Schwoerer, et al.
Nature Communications
|
March 24, 2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial
Sonja Loges, Michael Heuser, Jörg Chromik, et al.
Blood
|
September 27, 2019
Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group
Frank G Rücker, Mridul Agrawal, Andrea Corbacioglu, et al.
Page
of 2